Replimune Group Inc. stocks have been trading down by -15.79 percent following disappointing clinical trial news dampening investor confidence.
Click Here for a Millionaire's POV on Trading REPL
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- A second FDA Complete Response Letter found the IGNYTE trial for RP1 plus nivolumab in anti-PD-1–failed melanoma inadequate to prove effectiveness, hitting Replimune Group Inc. hard.
- Major banks including Wedbush, Leerink, Jefferies, H.C. Wainwright, JPMorgan, Piper Sandler, and Cantor Fitzgerald downgraded REPL, with several cutting price targets to $2 and flagging major uncertainty for RP1.
- Shares of REPL plunged about 62%–64% on huge volume after the FDA rejection of RP1’s BLA in melanoma, as analysts stripped out or deeply discounted the RP1 melanoma opportunity.
- Management, according to Jefferies, will not further develop RP1 without accelerated approval, leaving Replimune Group Inc.’s strategic path unclear.
- Law firms Johnson Fistel and Pomerantz LLP opened securities-law investigations tied to the RP1 BLA rejection and the ensuing stock collapse, adding legal overhang.
Weekly Update Apr 20 – Apr 24, 2026: On Saturday, April 25, 2026 Replimune Group Inc. stock [NASDAQ: REPL] is trending down by -15.79%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – negative
Replimune now sits as a distressed small-cap oncology platform with a compromised lead asset. Fundamentals are weak: negative ROE near -90%, ROA worse than -60%, and EBITDA of roughly -$68M underscore an uneconomic model at current scale. Operating cash burn of about $66M per quarter is only partly mitigated by a strong liquidity profile (current ratio 5.6, cash and short-term investments ~\$269M), implying ~2–3 years of runway, but with minimal revenue and no clear commercial path.
Technically, the stock is in a steep downtrend following the CRL-driven gap collapse on extreme volume, with subsequent sessions showing only fragile dead-cat bounces. The weekly tape from 1.83 to 2.88 and back to 2.40 highlights elevated volatility and failed attempts to sustain strength above \$2.80. Intraday 5-minute action shows sellers consistently capping rallies near the mid-\$2s. For trading, \$2.00 is the critical pivot: below it, downside momentum likely resumes; above \$2.80 would signal a tradable squeeze.
More Breaking News
- XRTX Stock Jumps As Kidney Pipeline Expands With VB4-P5 Deal
- REPL Stock Collapses As FDA Rejection Triggers Downgrades
- Organon Stock Surges As Traders Bet On $12B Takeover
- MAS Stock Climbs As Analysts Reassess Housing Cycle Risks
The second CRL for RP1 plus nivolumab, broad analyst downgrades to Hold/Sell, price targets cut to \$2–4, and emerging securities investigations collectively destroy the prior bull case and place Replimune well below healthcare and biotech benchmarks on risk-adjusted outlook. With RP1 effectively written off and no validated late-stage asset, the equity becomes a speculative option on residual pipeline or strategic interest. Fair risk-adjusted value sits around \$2, with resistance at \$2.80 and support at \$1.50.
Quick Financial Overview
Replimune Group Inc. is trading in the low single digits after the RP1 melanoma setback, with weekly prices swinging from $1.83 to $2.88 and closing the latest session around $2.40. That bounce from sub-$2 lows to an intraday high near $2.88 shows aggressive short-term dip buying, but the pullback toward $2.40 on the 5‑minute chart signals profit-taking and lingering selling pressure. For traders, this is classic post‑capitulation volatility, where sharp intraday ranges can cut both ways.
On the balance sheet, Replimune Group Inc. holds $122.95M in cash and $269.14M in cash plus short‑term investments, against total liabilities of $123.05M. Working capital of about $230.27M and a current ratio of 5.6 suggest near‑term liquidity is solid. Debt levels look manageable, with total debt to equity at 0.36 and long‑term debt around $72.27M, but that safety net is only as good as management’s ability to control burn.
The latest quarterly data show a net loss of about $70.93M and operating cash outflow of roughly $65.96M, driving a free cash flow of around -$66.09M. Returns are deeply negative, with return on equity near -47.39% and return on assets around -38.63%, reflecting a development‑stage biotech now missing its lead approval catalyst. REPL’s price to book ratio near 1.12 suggests traders are valuing it close to its net asset base, which often happens when the market stops paying for the old pipeline story and focuses on liquidation or optionality value.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.